API Holdings (Pharmeasy) Unlisted Shares
PharmEasy Valuation Slashed 92% From Peak In Latest Janus Henderson Filing
NDTV profit
2 min read
PharmEasy Valuation Plummets 92% in Latest Janus Henderson Filing.
Expert Analysis:
Valuation Reduction: API Holdings Pvt. (PharmEasy) valuation was cut by 92% to $460 million by Janus Henderson.
Valuation Drop: At the end of 2021, Janus Henderson valued PharmEasy at approximately $5.6 billion In the latest SEC filing, the value of these shares has dropped by 92%, reducing PharmEasy's worth to around $460 million.
Earlier Valuation Slash: The struggling e-pharmacy experienced a 90% reduction from its peak valuation in April this year when it raised Rs 1,800 crore, led by Ranjan Pai's Manipal Education and Medical Group and existing investors.
Revenue Growth: FY23 revenue increased 16% to Rs 6,644 crore, up from Rs 5,728.8 crore in FY22.
Losses Widened: The Company Losses widened to Rs 5,211.7 crore from Rs 3,992.4 crore in FY22. It faces increased competition from rivals like Tata 1mg, Medlife, Flipkart Health+, and Reliance-backed Netmeds.
PharmEasy's valuation slashed 92% to $460 million due to widening losses, modest revenue growth, and rising competition.
Precize Daily Pulse
The latest news in the world of Unlisted Shares, summarised by our experts.
Company
Our Office
Office No. 1219, The Summit Business Park, Andheri Kurla Road, Andheri East, Mumbai, Maharashtra - 400093
Find us on Googlesupport@precize.in
+91 7738336457
All trademarks and logos or registered trademarks and logos found on this Site or mentioned herein belong to their respective owners and are solely used for informational and educational purposes.
The material presented in this advertisement is for informational purposes only and should not be construed as investment advice or investment availability. It is not a recommendation of, or an offer to sell or solicitation of an offer to buy, any particular unlisted share, security, strategy, or investment product. Investing in the private market and securities involves risks, including the potential loss of money, and past performance does not guarantee future results. Market trends, data interpretations, graph projections are provided for informational and illustrative purposes and may not reflect actual future performance. Nothing on this website should be construed as personalized investment advice or should not be treated as legal, financial, or any other form of advice. Precize is not liable for financial or any other form of loss incurred by the user or any affiliated party based on information provided herein.
Precize is neither a stock exchange nor does it intend to get recognized as a stock exchange under the Securities Contracts Regulation Act, 1956. Precize is not authorized by the capital markets regulator to solicit investments. The securities traded on these platforms are not traded on any regulated exchange.
The website will be updated regularly.
Copyright © 2026 - Precize - All Rights Reserved